PuSH - Publication Server of Helmholtz Zentrum München: A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: Implications for clinical resistance in targeted cancer treatment.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

von Bubnoff, N.* ; Barwisch, S.* ; Speicher, M.R. ; Peschel, C.* ; Duyster, J.*

A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: Implications for clinical resistance in targeted cancer treatment.

Cell Cycle 4, 400-406 (2005)

DOI

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

The discovery of tyrosine kinases that, once deregulated, can cause malignancy, allowed the development of specifically acting anti-cancer compounds. In chronic myeloid leukaemia (CML), the Bcr-Abl kinase inhibitor imatinib (STI571, Gleevec) induces impressive response rates. However, resistance occurs especially in advanced phase CML and Ph + ALL, primarily as a consequence of point mutations within the Bcr-Abl kinase domain that prevent imatinib from binding. To overcome imatinib resistance, alternative Abl kinase inhibitors are finding their way into clinical trials. However, it is likely that resistance to second-generation compounds will occur as well. Therefore, it will be critical to determine specific resistance profiles for each particular compound. We recently devel- oped a cell-based screening strategy that allows one to predict the pattern and relative abundance of Bcr -Abl resistance mutations emerging in the presence of imatinib or an alternative Abl-kinase inhibitor. Using this strategy, the findings in inhibitor resistant sublines reflect observations made in CML patients with imatinib resistance, including Bcr-Abl mutations, amplification of the Bcr-Abl gene, and overexpression of the Bcr-Abl protein. We here provide a detailed methodological description, and discuss the impli- cations of this strategy for different clinically relevant oncogenic tyrosine kinases.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords targeted therapy; kinase inhibitors; resistance; Gleevec; imatinib; CML; Ph+ALL

ISSN (print) / ISBN 1538-4101

e-ISSN 1551-4005

Journal Cell Cycle

Quellenangaben Volume: 4, Issue: 3, Pages: 400-406

Publisher Landes Bioscience

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Human Genetics (IHG)